Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled Phase III Trial

AIMS: To evaluate the efficacy and safety of anagliptin added to metformin and empagliflozin 10 mg in adults with Type 2 diabetes (T2D) with inadequate glycaemic control. MATERIALS AND METHODS: In this multicentre, randomised, double-blind, placebo-controlled Phase III trial, participants receiving metformin (≥ 1000 mg/day) plus empagliflozin 10 mg/day were randomised 1:1 to anagliptin 100 mg twice daily or placebo for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) at Week 24 in the full analysis set, analysed using a mixed-effects model for repeated measures. Secondary endpoints included fasting plasma glucose (FPG), HbA1c target attainment, HOMA-β and safety. Glycaemic responder analyses were conducted post hoc. RESULTS: The full analysis set included 195 participants (anagliptin, n = 97; placebo, n = 98). At Week 24, LS mean HbA1c changes were -0.81% and -0.24%, respectively, yielding a treatment difference of -0.57% (95% CI -0.74 to -0.40; p < 0.0001). FPG was also significantly reduced (between-group difference -12.15 mg/dL, 95% CI -19.18 to -5.12; p = 0.0008). HbA1c ≤ 7.0% was achieved by 55.7% versus 25.5% of participants. HbA1c reductions ≥ 0.5% occurred in 68.0% versus 27.6%, and reductions ≥ 1.0% in 33.0% versus 9.2%. HOMA-β improved significantly with anagliptin (between-group difference 14.35, 95% CI 7.37-21.32; p < 0.0001). Treatment-emergent adverse events occurred in 22.7% and 17.2%, respectively; no hypoglycaemic events or deaths were reported. CONCLUSIONS: Anagliptin added to metformin and empagliflozin 10 mg provided confirmatory evidence of additional glycaemic efficacy in a separately randomised Korean population, increased glycaemic responder rates and improved estimated β-cell function, with acceptable short-term tolerability. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05814406.

Authors

Institutions

Publication Details

Journal
Diabetes Obesity and Metabolism
Published
2026-11-16
DOI
https://doi.org/10.1111/dom.71501
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled Phase III Trial

H. O. Cho, Jun Hwa Hong, Kyung Ah Han, Moon-Kyu Lee et al.
4 links
Diabetes Obesity and Metabolism
Diabetes Treatment and Management
article

Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled Phase III Trial

H. O. Cho, Jun Hwa Hong, Kyung Ah Han, Moon-Kyu Lee, Hae Jin Kim, Eun Sook Kim, Sang Yong Kim, Soojin Park, Young Sang Lyu
article en

Abstract

AIMS: To evaluate the efficacy and safety of anagliptin added to metformin and empagliflozin 10 mg in adults with Type 2 diabetes (T2D) with inadequate glycaemic control. MATERIALS AND METHODS: In this multicentre, randomised, double-blind, placebo-controlled Phase III trial, participants receiving metformin (≥ 1000 mg/day) plus empagliflozin 10 mg/day were randomised 1:1 to anagliptin 100 mg twice daily or placebo for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) at Week 24 in the full analysis set, analysed using a mixed-effects model for repeated measures. Secondary endpoints included fasting plasma glucose (FPG), HbA1c target attainment, HOMA-β and safety. Glycaemic responder analyses were conducted post hoc. RESULTS: The full analysis set included 195 participants (anagliptin, n = 97; placebo, n = 98). At Week 24, LS mean HbA1c changes were -0.81% and -0.24%, respectively, yielding a treatment difference of -0.57% (95% CI -0.74 to -0.40; p < 0.0001). FPG was also significantly reduced (between-group difference -12.15 mg/dL, 95% CI -19.18 to -5.12; p = 0.0008). HbA1c ≤ 7.0% was achieved by 55.7% versus 25.5% of participants. HbA1c reductions ≥ 0.5% occurred in 68.0% versus 27.6%, and reductions ≥ 1.0% in 33.0% versus 9.2%. HOMA-β improved significantly with anagliptin (between-group difference 14.35, 95% CI 7.37-21.32; p < 0.0001). Treatment-emergent adverse events occurred in 22.7% and 17.2%, respectively; no hypoglycaemic events or deaths were reported. CONCLUSIONS: Anagliptin added to metformin and empagliflozin 10 mg provided confirmatory evidence of additional glycaemic efficacy in a separately randomised Korean population, increased glycaemic responder rates and improved estimated β-cell function, with acceptable short-term tolerability. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05814406.

Diabetes Obesity and Metabolism
Eulji University (KR), University of Ulsan (KR), Chosun University Hospital (KR), Daejeon Eulji Medical Center, Eulji University (KR), Keimyung University Dongsan Medical Center (KR), JW Pharmaceutical (South Korea) (KR), Ulsan University Hospital (KR), Eulji University Uijeongbu Eulji Medical Center (KR), Keimyung University Daegu Dongsan Hospital (KR), Eulji University Nowon Eulji Medical Center (KR), Keimyung University Dongsan Hospital (KR), Keimyung University (KR), Ajou University (KR)
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon